566:SGXSHS Holdings Ltd. Analysis
Data as of 2026-06-07 - not real-time
SGD 0.11
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
SHS Holdings trades at SGD 0.113, far below its DCF‑derived fair value of roughly SGD 2.05, implying a massive undervaluation on a price‑to‑book basis of 0.5 and a price‑to‑sales of 0.26. The technical picture is bearish, with the 20‑day SMA (0.115) just under the 50‑day SMA (0.115), a negative MACD histogram and an RSI of 38 indicating limited upside momentum, while volume is decreasing and price is hovering near the identified support of SGD 0.11. Insider activity adds a positive note, as recent filings show insiders increasing their holdings by 25% over the past year, suggesting confidence in a turnaround. However, the company reports negative operating and net margins (‑5.8% and ‑4.9% respectively), a trailing EPS of –0.02 and a ROE of –9.4%, highlighting ongoing profitability challenges.
The balance sheet shows modest cash (SGD 66.9 m) against comparable debt (SGD 70.4 m) and a debt‑to‑equity of 50%, while free cash flow remains positive at SGD 34.7 m, providing some cushion. The dividend yield of 2.03% appears attractive but is unsustainable given the negative earnings and a payout ratio of 65% on a loss base. High 30‑day volatility (≈32%) and a negative beta (‑0.20) indicate price swings and an inverse market correlation, while the company's multi‑country exposure adds medium geographic and currency risk. Overall, the stock sits at a crossroads between deep valuation appeal and significant operational and market headwinds.
The balance sheet shows modest cash (SGD 66.9 m) against comparable debt (SGD 70.4 m) and a debt‑to‑equity of 50%, while free cash flow remains positive at SGD 34.7 m, providing some cushion. The dividend yield of 2.03% appears attractive but is unsustainable given the negative earnings and a payout ratio of 65% on a loss base. High 30‑day volatility (≈32%) and a negative beta (‑0.20) indicate price swings and an inverse market correlation, while the company's multi‑country exposure adds medium geographic and currency risk. Overall, the stock sits at a crossroads between deep valuation appeal and significant operational and market headwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical indicators (MACD, RSI) near support
- Decreasing volume suggesting limited short‑term buying pressure
- Insider buying provides a modest confidence boost
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value far exceeds current market price
- Positive free cash flow despite earnings losses
- Insider ownership increase indicating belief in turnaround
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Structural undervaluation on book and sales multiples
- Diversified geographic footprint reducing single‑market exposure
- Potential for margin improvement through operational restructuring
Key Metrics & Analysis
Financial Health
Revenue Growth323.70%
Profit Margin-4.99%
ROE-9.37%
ROA-3.55%
Debt/Equity50.48
P/B Ratio0.5
Op. Cash FlowSGD6.1M
Free Cash FlowSGD34.7M
Industry P/E30.2
Technical Analysis
TrendBearish
RSI38.1
SupportSGD 0.11
ResistanceSGD 0.12
MA 20SGD 0.12
MA 50SGD 0.12
MA 200SGD 0.12
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02
Valuation
Fair ValueSGD 2.05
GradeUndervalued
TypeValue
Dividend Yield2.03%
Risk Assessment
Beta-0.20
Volatility31.81%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.